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Abstract
Background: Health authorities in several countries recently recommended the expansion of human immunodeficiency
virus (HIV) antibody testing, including the use of rapid tests. Several HIV rapid tests are now licensed in Europe but their
sensitivity on total blood and/or oral fluid in routine healthcare settings is not known.
Methods and Findings: 200 adults with documented HIV-1 (n=194) or HIV-2 infection (n=6) were prospectively screened
with five HIV rapid tests using either oral fluid (OF) or finger-stick whole blood (FSB). The OraQuick Advance rapid HIV1/2H
was first applied to OF and then to FSB, while the other tests were applied to FSB, in the following order: Vikia HIV 1/2H,
Determine HIV 1–2H, DetermineH HIV-1/2 Ag/Ab ComboH and INSTI HIV-1/HIV-2H. Tests negative on FSB were repeated on
paired serum samples. Twenty randomly selected HIV-seronegative subjects served as controls, and the results were read
blindly. Most patients had HIV-1 subtype B infection (63.3%) and most were on antiretroviral therapy (68.5%). Sensitivity was
86.5%, 94.5%, 98.5%, 94.9%, 95.8% and 99% respectively, with OraQuick OF, OraQuick FSB, Vikia, Determine, Determine Ag/
Ab Combo and INSTI (p,0.0001). OraQuick was less sensitive on OF than on FSB (p=0.008). Among the six patients with
three or more negative tests, two had recent HIV infection and four patients on antiretroviral therapy had undetectable
plasma viral load. When patients positive in all the tests were compared with patients who had at least one negative test,
only a plasma HIV RNA level ,200 cp/ml was significantly associated with a false-negative result (p=0.009). When the 33
rapid tests negative on FSB were repeated on serum, all but six (5 negative with OraQuick, 1 with INSTI) were positive. The
sensitivity of OraQuick, Determine and Determine Ag/Ab Combo was significantly better on serum than on FSB (97.5%,
p=0.04; 100%, p=0.004; and 100%, p=0.02, respectively).
Conclusion: When evaluated in a healthcare setting, rapid HIV tests were less sensitive on oral fluid than on finger-stick
whole blood and less sensitive on finger-stick whole blood than on serum.
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Introduction
Late diagnosis of human immunodeficiency virus (HIV) infection,
resulting in delayed patient management, is associated with poorer
survival [1]. About one-third of new diagnoses in industrialized
countries are made when the patient is already severely immunosup-
pressed [2,3], while in developing countries more than 80% of patients
are diagnosed at an advanced clinical stage [4,5]. In the United States,
the Centers for Diseases Control and Prevention have recommended
extending HIV antibody testing to people aged 13–64 years [6]. Such
a program would be implemented in a variety of healthcare settings,
such as hospital emergency departments, and could involve disposable
rapid HIV diagnostic tests, the patient receiving the necessary
information at the same site [6]. Such HIV rapid tests use finger-stick
capillary whole blood (FSB) or oral fluid (OF), thus avoiding the need
for venous blood sampling and centrifugation.
Medical laboratories have been using these rapid tests for more
than two decades to test serum and plasma, particularly in
developing countries and for emergency diagnosis [7]. They are
simple to use but lack sensitivity relative to reference enzyme
immunoassays (EIA), particularly during primary HIV infection
and infection by variant strains [8].
In the EU, these tests must first undergo validation studies of
sensitivity and specificity against panels of frozen sera or plasma
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variants, previously tested with reference EIA and Western blot
methods [9,10]. Sensitivity testing of rapid tests on whole blood
and oral fluid is hindered by the need to test fresh samples and by
the lack of a reference panel. No real-time comparisons of such
HIV tests are available. Following recent French recommenda-
tions to extend HIV testing [11], including the use of rapid testing
when necessary, the French agency for health product safety
(Afssaps) mandated us to carry out a real-time comparison of the
sensitivity of the five approved rapid tests on samples from patients
with documented HIV infection.
Materials and Methods
Two hundred consecutive adults with documented HIV
infection and 20 HIV-seronegative volunteers, included to permit
blinded test reading, were prospectively recruited in our outpatient
clinic in Saint Louis Hospital, Paris, France, from December 2008
to February 2009, with their written informed consent. The study
was approved by the Paris-Saint-Louis ethics committee and the
Afssaps scientific board.
HIV-1 or HIV-2 infection had previously been confirmed by
western blot positivity. (Biorad, New Lav blot, Paris, France). The
patients’ characteristics (age, sex, CDC stage, geographic origin,
HBV and HCV serostatus, antiretroviral therapy, date of HIV
infection, CD4 cell count) and the HIV-1 subtype were obtained
from our computerized database. Plasma viral load was deter-
mined by using the Cobas TaqManH (Roche V1.0, Meylan,
France) or Abbott RealTimeH method (Abbott Molecular, Rungis,
France), and the viral genotype was determined in patients
infected with HIV-1 group M by polymerase gene sequencing
(ViroSeqH, Celera-Abbott). When viral load was undetectable or
the patient was infected by a variant, serotyping was used to
differentiate between subtype B and non B anti-V3 antibodies, and
between anti-HIV-2 and anti-HIV-1 group O antibodies [12].
The five rapid HIV tests approved in Europe for use on FSB or
OF were performed in the following order on samples from each
subject: OraQuick Advance Rapid HIV 1/2 antibody testH
(Orasure/Orgentec) was performed first on oral fluid (OF) and
then on finger-stick whole blood (FSB), followed by the other four
tests on FSB: Vikia HIV 1/2H (bioMe ´rieux), Determine HIV 1–2H
(Unipath, Inverness), DetermineH HIV-1/2 Ag/Ab ComboH
(Determine 4G for 4
th generation; Unipath, Inverness) and INSTI
HIV-1/HIV-2H (Biolytical, Nephrotek). The particularity of the
DetermineH HIV-1/2 Ag/Ab ComboH test is that it detects both
P24 antigen and anti-HIV antibodies and can therefore potentially
reduce the window of seronegativity during primary infection [13].
The same batch of tests was used throughout the study. The
characteristics of the rapid tests are summarized in Table 1.
The tests were done by two physicians and two technicians
specially trained for the study, in keeping with the manufacturers’
recommendations. Oral fluid was obtained with a swab, between
the upper and lower teeth and gums, following the manufacturers’
instructions. Finger-stick whole blood was obtained with a
microlancet after hand warming. In case of insufficient sample
volume, patients underwent a second finger-stick. Blood was
collected with a capillary tube and immediately deposited on the
different test strips, as recommended. After 20 minutes (except for
the INSTI test, which is read immediately), all the tests were read
by a single investigator, different from the one who performed the
tests. Consequently, the reader was unaware of the subjects’ HIV
serostatus between HIV-infected patients and healthy volunteers.
Venous blood was drawn at the same time and serum was
isolated by centrifugation (10 min, 3000 g) and stored at 220uC
until use. The results were recorded as positive, weakly positive
(faint band), negative or invalid (non reactive internal control). In
case of false-negative and/or invalid results, the patient’s serum
sample was thawed and retested with the corresponding falsely
negative or invalid rapid test(s) and EIA. A fourth-generation EIA,
the ArchitectH i2000SR Abbott HIV1/2 assay was considered the
gold standard because of its high sensitivity for early seroconver-
sion [14]. ArchitectH i2000SR assays were performed on stored
frozen samples. P24 HIV-1 antigen, when present, was quantified
with the Vidas HIV-1 p24 Antigen assay (bioMe ´rieux, Marcy
l’Etoile, France).
Statistical analysis
The sensitivity of the different tests was defined as the number of
positive and weakly positive tests divided by the number of valid
tests. Sensitivity on the 6 different tests was compared using a
logistic regression model using generalized estimating equations
(GEEs) approach to take into account correlated data [15]. The
Table 1. Technical characteristic of EU-approved HIV screening rapid tests for use on whole blood and/or oral fluid.
Test Manufacturer
Principle and antigens coated
on membrane solid phase
Binding revelation
reagents
Procedural Control
coated on solid phase
Volume Time
for reading
Oraquick ADVANCE
Rapid HIV-1/2
Antibody test
Orasure
technologies (USA)
Immunochromatography HIV1
group M – group O (gp41) and
HIV2 (gp36)
synthetic peptides
Protein A labelled
with reddish purple
Goat anti human Ig G 5 mL blood oral fluid
cravicular collection
20–40 mn
VIKIA HIV 1/2 bioMe ´rieux (France) Immunochromatography HIV1
group M - group O (gp41) and
HIV2 (gp36) synthetic peptides
Antigens linked to blue
colored microspheres
Colored bovine serum
albumin
75 mL 20–30 mn
Determine HIV 1–2 Orgenics Ltd (Israel) Immunochromatography HIV1
(gp41) and HIV2 (gp36) recombinant
proteins synthetic peptides
Antigens linked to
colloidal selenium
Anti HIV antibodies HIV
peptide
50 mL 15–60 mn
INSTI HIV K Biolytical (Canada) Immunofiltration HIV1 (gp41) and
HIV2 (gp36) recombinant proteins
Protein A labelled
with blue indigo
Protein A 50 mL
5m n
Determine Combo
Ag AC HIV 1–2
Orgenics Ltd (Israel) Immunochromatography 1/HIV1 (gp41)
and HIV2 (gp36) recombinant proteins
synthetic peptides 2/Avidine to capture
anti p24 labelled antibodies
Antigens linked to
colloidal selenium Anti
HIV-1 p24 antibodies
linked to biotin
No data available 50 mL 15–60 mn
doi:10.1371/journal.pone.0011581.t001
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sensitivities of the OraQuick test on OF versus FSB [16]. The
same statistical test was used to compare the sensitivity of the
different rapid tests on FSB, and to compare the sensitivity of these
tests on either FSB or serum. Indeed, rapid tests which were falsely
negative on FSB were repeated on the corresponding sera. We did
not repeat all the tests on serum, assuming that tests positive on
FSB would also be positive on serum.
Baseline characteristics of the patients in whom all the tests were
positive were compared with those of patients with at least one
negative test, using the chi-square test and Wilcoxon rank sum test
in order to identify factors associated with false-negative results. A
p value of ,0.05 was considered to denote statistical significance.
The SAS 9.1 software package (SAS Inc, Cary, NC) was used for
all analyses.
Results
The HIV-infected patients were mostly men (83%) of European
origin (59.8%), with HIV-1 subtype B infection (63.3%), under
antiretroviral therapy (68.5%), and with plasma HIV-1 RNA
,200 cp/ml (57.8%). Their median CD4 cell count was 437/
mm
3. Patient acceptance of this protocol was particularly high, as
recruitment took place during quarterly follow-up visits by the
patients’ usual doctors.
Sensitivity was 86.5% [81–90.5] with OraQuick OF, 94.5%
[90.4–96.9] with OraQuick FSB, 98.5% [95.6–9.5] with Vikia,
94.9% [90.8–97.2] with Determine, 95.8% [91.6–97.9]] with
Determine 4G and 99% [96.3–99.7 with INSTI (p,0.0001).
OraQuick was significantly less sensitive on OF than on FSB
(p=0.008). The sensitivity of OraQuick on OF was also
significantly lower than the sensitivity of the tests using FSB
(p=0.0002, 0.006, 0.0002, and 0.004 for Vikia, Determine,
INSTI and Determine 4G, respectively). The sensitivity of
OraQuick and Determine on FSB was significantly lower than
that of INSTI (p=0.025 and 0.03, respectively).
Overall, 60 tests (5.2%) were falsely negative on samples from
36 patients. Among the six patients with three or more negative
tests, two had recent HIV infection, and four had undetectable
plasma viral load on antiretroviral therapy; one of the latter
patients was infected by HIV-1 group O. The 2 seroconventer
patients were infected by HIV-1 subtypes B and F, less than 2
months previously. Recent infection was confirmed by a weakly
positive 4
th generation EIA test and by Western blot profiles
showing a typical seroconversion pattern with isolated Gag-Env
weak reactivity in both subjects without Pol p31 band [17].
Western blot follow up confirmed the seroconversion in both
cases. Their viral loads were 5 206 179 and 14 836 copies/ml,
respectively. P24 antigen was detectable at 380 pg/ml in the
plasma of the first patient but was not detectable in the other
patient. All rapid tests were negative in both patients, with the
exception of the INSTI test, which was weakly positive in the latter
patient. No P24 antigen band was seen in the Determine 4G test in
either of the patients with recent infection.
Four other patients had three or more negative rapid tests:
N Only the Vikia and INSTI tests were positive in a 34-year-old
man with HIV-1 group O infection. Viral load was
undetectable on HAART and his CD4 cell count was 159/
mm3. When tested on serum, only OraQuick remained
negative.
N Only the Vikia and INSTI rapid tests were positive (weak
reactivity) in a 42-year-old Caucasian man who was diagnosed
with HIV-1 B subtype infection in March 2005. His viral load
was undetectable on HAART and his CD4 cell count was
675/mm
3. When tested on serum, OraQuick remained
negative.
N OraQuick (OF and FSB) Vikia, Determine and Determine 4G
were negative in a 40-year-old Caucasian man diagnosed with
HIV-1 subtype B infection in March 1999. Viral load was
undetectable on HAART and his CD4 cell count was 861/
mm3. When tested on serum, only OraQuick remained
negative.
N The OraQuick (OF and FSB) and INSTI tests were negative in
a 27-year-old woman of African origin who had been
diagnosed with HIV infection (indeterminate subtype) in
September 2004. Her viral load was undetectable on HAART
and her CD4 cell count was 831/mm3. INSTI remained
negative on serum and OraQuick was weakly positive.
Among the six patients with HIV-2 infection, two had a false-
negative OraQuick test on OF but both were positive on FSB.
These two patients were receiving antiretroviral therapy and their
plasma viral load was undetectable in an HIV-2-specific assay. All
20 HIV-negative controls were negative in all the rapid tests. Of
note, 39 (3.2%) tests were invalid, owing the absence of the control
line. The Determine 4G test gave 33 invalid results (16.5%)
(Table 2).
Among the 18 patients (33 tests) with at least one negative FSB
test, all but six had positive results on serum (5 negative with
OraQuick previously falsely negative in FSB and 1 with INSTI)
(Table 3). These 6 patients with negative rapid tests on serum were
the same as those with at least three negative tests on FSB (see
above), i.e. the two patients with recent HIV-infection, and four
patients with undetectable plasma viral load on antiretroviral
Table 2. Sensitivity of five rapid HIV tests in 200 HIV-infected patients, using either oral fluid (OF) or finger-stick whole blood (FSB).
Oraquik OF Oraquick FSB Vikia FSB Determine FSB INSTI FSB Determine 4G FSB
Invalid test 00 04 23 3
Negative test 27 11 3 10 2 7
Weakly positive test* 10 6 1 1 4 7
Positive test 163 183 196 185 192 153
Overall sensitivity %
of valid tests [95% CI]
86.5%
[81–90.5]
94.5%
[90.4–96.9]
98.5%
[95.6–99.5]
94.9%
[90.8–97.2]
99%
[96.3–99.7]
95.8%
[91.6–97.9]
Sensitivity was calculated by dividing the sum of positive and weakly positive tests by the number of valid tests. Tests without a visible control line were considered
invalid.
*only a faint band was visible, but the test was considered positive.
doi:10.1371/journal.pone.0011581.t002
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been positive on serum, the sensitivities of OraQuick, Determine
and Determine 4G were significantly better on serum than on FSB
with 94.5% [90.4–96.9] vs 97.5% [94.2–98.9] p=0.04, 94.9%
[90.8–97.2] vs 100% [98.1–100], p=0.004, and 95.8% [91.6–
97.9] vs 100% [98–100], p=0.02, respectively (Table 3). When
the 39 tests with invalid results on FSB were repeated on serum,
only four remained invalid (all with the Determine 4G).
The P24 band of the Determine 4G test was never positive on
FSB, even in the patient with 380 pg P24/ml of serum. Determine
4G was also negative for P24 antigen on serum from this patient.
Only plasma HIV-1 RNA level below 200 copies/ml and
elevated CD4 cell counts were significantly associated with the risk
of having at least one negative test. However, the significant
association (p=0.04) with the CD4 cell count disappeared in
multivariate analysis and only plasma HIV RNA ,200 cp/ml
remained significantly associated with the risk of having at least
one false-negative result (odds ratio: 3.67, 95% CI: 1.52–8.84,
p=0.009) (Table 4).
HIV genetic diversity in our population was high, with 36.7% of
non B subtypes and a large panel of complex recombinant strains.
Six patients were also infected by HIV-2 and one by HIV-1 group
O. Table 5 summarizes the results according to the type and
subtype. There was no significant difference in sensitivity among
the different rapid tests for B or non B HIV-1 subtype infection
(Fischer exact test, p.0.25).
Discussion
This is the first study to compare the sensitivity of EU-approved
rapid HIV screening tests, on oral fluid, capillary blood and serum.
Among the 200 HIV-infected volunteers included in this study,
rapid test sensitivity ranged from 86.5% [81–90.5] to 99% [96.3–
99.7]. Thirty-six patients had a false-negative result in at least one
of the six tests. OraQuick was the least sensitive test on both OF
and whole blood and also yielded the largest number of ‘‘weakly
positive’’ results. OraQuick sensitivity improved from 86.5% to
94.5% (p=0.008) when FSB rather than OF was used, and to
97.5% when serum was used (p=0.04, Table 3). On testing serum
from patients with false-negative tests on FSB, only six tests
remained falsely negative (OraQuick in 5 cases, INSTI in one
case). These rapid tests are usually used to screen patients exposed
to or suspected of being infected by HIV. In this indication, it is
recommended to use two tests simultaneously to improve
Table 3. Sensitivity of five rapid HIV tests in 200 HIV-infected patients, combining the results for finger-stick whole blood and,
when the latter was negative, for serum.
Oraquick FSB Vikia FSB Determine FSB INSTI FSB Determine 4G FSB
Positive test in serum 6/11 3/3 10/10 1/2 7/7
Overall serum
sensitivity % [95% CI]
97.5% [94.2–98.9] 100% [98.1–100] 100% [98.1–100] 99.5% [97.2–99.9] 100% [98–100]
P 0.04 0.25 0.004 1 0.02
Differences in sensitivity between whole blood and serum were analyzed with the Mc Nemar test for paired samples.
doi:10.1371/journal.pone.0011581.t003
Table 4. Comparison of patient characteristics according to HIV screening rapid tests results on whole blood and/or oral fluid
results.
All tests positive $1 negative test
p-value uni-variate
analysis
p-value multi- variate
analysis
n=164 n=36
Median age (years) 41 44.5 0.24
Female (n, %) 28 (17%) 6 (16.6%) 1.00
CDC stage C (n,%) 37 (22.5%) 11(30.5%) 0.39
Caucasian 93 (57.1%) 26 (72.2%) 0.24
Sub-Saharan African 53 (32.5%) 8 (22.2%)
Other 17 (10.4%) 2 (5.6%)
HBV or HCV infection (n,%) 16 (9.8%) 3 (8.3%) 1.00
ARV therapy (n,%) 108 (65%) 29 (80.5%) 0.11
Date of HIV infection #2002 96 (58.5%) 19 (52.8%) 0.58
Median CD4 cell count 416 500 0.04 0.11
HIV VL ,200 cp/ml (n,%) 87 (53.1%) 29 (80.5%) 0.004 0.009
HIV-1 B subtype (n,%) 106 (64.6%) 20 (55.6%) 0.34
HIV-2 4 (2.4%) 2 (5.5%)
HIV-O 1 (2.5%)
others 2 recent infection
doi:10.1371/journal.pone.0011581.t004
HIV Rapid Tests Sensitivity
PLoS ONE | www.plosone.org 4 July 2010 | Volume 5 | Issue 7 | e11581sensitivity [18,19]. In our population, most of the patients were
already treated and 29 (80.5%) of the 36 patients with at least one
negative rapid test had undetectable viral load. This relation with
undetectable viral load was significant in both univariate
(p=0.004) and multivariate analysis (p=0.009) (Table 4).
In a study of 327 patients, Delaney found more false-negative
results with OraQuick on OF than on whole blood (99.1% versus
99.7%) [20]. Likewise, in a study of 81 patients in South Africa,
the sensitivity of OraQuick was only 96.3% on OF, compared to
100% on whole blood [21]. In a study of 139 patients, the
sensitivity of OraQuick was lower on OF (97.8%, with 3 false-
negatives) than on serum or plasma (100%) [22]. In these studies,
all the patients with false-negative OraQuick results had
undetectable viral load on antiretroviral therapy. The relation
between falsely negative oral fluid rapid tests and antiretroviral
therapy is well established and explains why in our study, with a
large proportion of patients on antiretroviral therapy, we obtained
a sensitivity of only 86.5% [81–90.5] with OraQuick on OF. This
lower sensitivity on oral fluid from treated patients has previously
been reported, but not in a study comparing different assays
simultaneously. Some of the rapid test evaluated here were
reactive with a large majority of the samples, whatever the
patients’ status. Lower reactivity due to treatment was a problem
with some assays but not with others. The lower sensitivity of OF
tests in patients on treatment is mentioned in the package inserts.
Physicians must be aware of this limitation, as some such patients
(if unconscious, for example) may be unable to state their HIV
serostatus.
The negativity of rapid tests on whole blood from the two
patients with recent infection confirms their lack of sensitivity
during this period. However, except for OraQuick, all the tests
were reactive on serum from both patients. These patients had
specific antibodies on Western blot (WB) and one already had
undetectable P24 antigenemia, indicating that they were in the
later stages of primary infection. Evaluation of rapid tests for
diagnosis of recent HIV infection in healthcare settings is hindered
by the difficulty of recruiting such patients, but the lack of rapid
test sensitivity in this setting has already been underlined. In 2007,
Stekler et al reported three cases of recent HIV infection (less than
6 months) with negative OraQuick results on whole blood [23]. In
2009, the same authors reported the limits of OraQuick rapid
testing on OF and FSB in the USA [24]. Rapid testing was positive
in 153 (91%) of 169 HIV-infected men who have sex with men, all
of whom were positive by EIA and/or nucleic acid testing.
Fourteen patients with primary infection and one profoundly
immunodepressed patient were positive in a 4
th generation EIA
test detecting both P24 antigen and anti-HIV antibodies [24].
Such combined assays are highly sensitive, detecting less than 15
picograms of P24/ml [25]. P24 antigen detection is useful for
closing the primary infection ‘‘window’’ period [17]. Determine
4G, the first such rapid test, needs to be made more sensitive, as
none of the whole-blood samples from our 200 patients reacted
with the P24 antigen line. This could be due to the relatively early
stage of HIV infection and to the control of viral replication by
treatment or to the African origin of many of our patients (61
cases). Similarly, Tardy et al, using serum samples from HIV-
infected patients positive for P24 antigen, found that none of the
17 patients with less than 50 pg of P24 antigen per milliliter of
serum was positive for P24 in the Determine 4G test, while only 4
of the 9 patients with values between 50 and 400 pg/ml were
positive [26]. There is insufficiency of literature on rapid test in
health care setting with recent HIV infection due to the difficulty
to include such patients [23,24,27]. This lower sensitivity of rapid
tests during primary HIV infection increases the risk of
misdiagnosis in patients with active viral replication and a high
risk of transmission, implying that these tests should be used with
care, particularly on OF or whole blood, in populations with a
high incidence of HIV infection, especially in primary care or
emergency settings [28]. Possible explanations for this lower
sensitivity of rapid tests include weaker antibody affinity due to
hemolysis, dilution in whole blood, the short migration or filtration
time for antigen-antibody binding, and reaction at room
temperature instead of 37uC as in EIA tests [29].
HIV antigenic diversity has been implicated in poor antibody
detection by rapid tests, particularly in case of variant or primary
infection [8,27]. In our study, the difference in the frequency of
false-negative results for subtype B and non B HIV-1 group M was
not statistically significant. HIV screening tests use synthetic
antigens based on sequences of HIV-1 subtype B viruses that
circulate in western countries. In case of HIV-1 non B or highly
Table 5. Sensitivity of rapid test detection according to the HIV genotype.
N 199* Oraquick OF Oraquick FSB Vikia FSB Determine FSB Insti FSB Determine 4G FSB
HIV-1 Subtype B 126 Positive (%) 111 (88) 119 (94) 124 (97) 118 (94) 123 (97) 96 (76)
Negative 15 7 2 5 1 5
Invalid - - - 32 2 5
HIV-1 Subtype
Non B**
58 Positive (%) 51 (87) 55 (94) 57 (98) 52 (89) 58 (100) 49 (84)
Negative 731 5 - 2
Invalid --- 1 - 7
HIV-2 6 Positive 466 6 6 6
Negative 2- - - - -
not typable 9 Positive 789 9 8 8
Negative 21- - 1 -
Invalid --- - - 1
*Failure from PCR, serotyping insufficient volume in one sample;
**HIV-1 Subtype non B: A (3); D (2); F (2); J (1); O (1); CRF01 (3); CRF02 (17); CRF06 (1); CRF19 (1); Recombinant B/CRF02 (1); Complex recombinant (2); Serotyped as non B
(24). Fischer exact test, p.0.25.
doi:10.1371/journal.pone.0011581.t005
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be limited, particularly during the seroconversion phase [30].
HIV-2 infection was detected by all the tests used here, except for
OraQuick oral fluid, which missed two cases. A patient infected by
HIV-1 group O was negative in the OraQuick blood and OF tests
and also in both Determine tests. The poor performance of the
rapid tests for the patient infected by HIV-1 group O in this study
confirms the difficulty of recognizing this rare variant [31]. It is
noteworthy that HIV-2 and HIV-O account for 2% of all new
infections each year in France [32]. In addition, rapid tests are
widely used in sub-Saharan Africa, where such viruses circulate at
higher levels.
Post-marketing studies of the OraQuick test on whole blood and
oral fluid showed a lack of specificity, with positive predictive
values of 90.00% (range: 50.00–100%) for OF and 99.24% (range:
66.67–100%) for FSB [33]. In a more recent study, the specificity
of OraQuick on OF declined significantly as the end of the shelf
life approached [34]. Owing to the design of this study, focusing
only on sensitivity in patients with known infection and using only
a small number of HIV-negative patients to blind the reading
procedure, we are unable to evaluate positive or negative
predictive values. The accuracy of diagnostic tests depends on
the prevalence of a disease in the population. This is of particular
importance in highly endemic countries where test positivity has a
high probability of being truly positive. Whatever the test, the
strategy and the clinical setting, quality control remains crucial
[35] and these devices are not considered alone sufficient to
confirm HIV infection. International guidelines recommend that,
whatever the HIV prevalence, a positive rapid test must be
confirmed by EIA or at least one other rapid test [18]. WHO
recommends using a first assay with 100% sensitivity and good
specificity [18]. In case of positivity, the confirmatory assay should
have 100% specificity and good sensitivity. This strategy is not
easy in practice, and a recent study performed in Africa using
current diagnostic tests and recommended algorithms clearly
underlined the need for well-evaluated and high-quality rapid tests
[36].
All the tests were easy to interpret, including the internal
procedural control, with the exception of the 4th generation
Determine test. The high rate of invalid 4th generation Determine
results (16%), due to the lack of control band reactivity, could be
due to high antibody titers consuming the conjugate at the test line
and/or to non specific slower migration with whole blood and/or
avidin-biotin-anti-P24 antibodies competing with the reagent
included in the strip and patient antibodies. Alternatively, the
low anti-HIV antibody titers in our treated population could
interfere with binding to the control band. This phenomenon was
less frequent with the corresponding serum samples, showing that
the use of whole blood hinders sample migration and/or antigen-
antibody binding on the test strip. Unreliable internal controls are
a major drawback. Rapid tests usually have neutral migration
controls rather than the positive and negative reaction controls
used in EIA methods. This lack of proper controls is a further
drawback.
Our study has several limitations. In particular, its size was
somewhat limited and the results we obtained are potentially only
applicable to the population studied, i.e. mostly patients infected
with HIV-1 subtype B, having undetectable plasma HIV RNA
levels and high CD4 cell counts on antiretroviral therapy. We were
only able to enroll two patients with recent HIV infection. Also,
owing to the study design, with five tests performed simultaneously
in the same order, technical problems such as insufficient OF or
blood volume for some tests may have affected the results.
However, we took these issues into account, notably by repeating
the finger-stick procedure if necessary. The sensitivity results were
not influenced by the order in which the tests were performed. For
example, INSTI was the last test but had one of the highest
sensitivities (99%). Finally, we compared the sensitivity of FSB
with that of serum, although we repeated only negative FSB tests,
assuming that patients with positive FSB results would also be
positive on serum. The need for fresh blood samples collected at a
point of care hinders repeatability studies but, as shown by the
overlapping confidence limits of the different tests, the statistically
significant differences in sensitivity might not be confirmed if the
study were to be repeated.
In conclusion, this first study comparing different EU-approved
HIV rapid tests in a healthcare setting confirms that the such tests
should be used with caution on whole blood and OF, especially in
patients with recent infection and in patients on antiretroviral
therapy. The tests all tended to perform better on serum than on
finger-stick blood or oral fluid. Given their potentially important
public health implications, these limitations need to be confirmed
in further real-time studies.
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